BRAF mutations in colorectal cancer are linked to loss of hMLH1 expression and proximal location, while independent of K-RAS activation

Anna Colomer 1, Nadina Erill 1, August Vidal 2, Ruth Román 1, Montse Verdú 2, Carlos Cordon-Cardo 3, Xavier Puig 1,2.

1BIOPAT, Grup Assistència, Barcelona, Spain; 2HISTOPAT Laboratoris, Barcelona, Spain; 3Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

The RAF gene family encodes RAS-regulated kinases that mediate cellular responses to growth signals. Mutations within the BRAF gene occur in about 10% of colorectal cancers, and are significantly associated to defective mismatch repair (MMR) due […]

2004-07-23T17:02:21+00:00

Microsatellite analysis of chromosome 18 in colorectal cancer

Erill N1, Colomer A1, Calvo M3, Vidal A2, Román R 1, Verdú M2, Cordon-Cardo C4, Puig X 1,2.

1BIOPAT, 2HISTOPAT Laboratoris, 3Statistics Dept. of the Universitat de Barcelona, Spain; and 4Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

Chromosome 18q allelic loss (c18q LOH) seems to have prognostic significance in stage II colorectal carcinoma. In our laboratory c18q LOH was prospectively analyzed in a series of primary colorectal tumors using five markers (D18S55/58/61/64 and 69). Results of 207 PCR-based assays […]

2003-07-23T17:00:47+00:00

Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas

Anna Colomer,1 Nadina Erill,1 Montse Verdú,2 Ruth Roman,1 August Vidal,1,2 Carlos Cordon-Cardo,1,3 Xavier Puig1,2

1BIOPAT, Grup Assistència, Barcelona; 2HISTOPAT Laboratoris, Barcelona; and 3Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

Multiple studies using primary tumors have reported that alterations in p53 expression and detection of TP53 mutations are associated with clinical aggressiveness and poor response to specific therapies.  However, there is no general agreement regarding the optimal technical approach to the analysis of p53.  We have studied a series of […]

2003-07-23T16:51:27+00:00

Molecular evaluation of TP53 status in human colorectal and urinary bladder cancer: phenotype versus genotype analysis

Erill N1, Colomer A1, Verdú M2, Román R1, Vidal A2, Condom E2, Banús JM3, Cordón-Cardo C1,2, Puig X1,2.

1BIOPAT. Grup Assistència, 2HISTOPAT Laboratoris & 3ICUN. Institut Català d’Urologia i Nefrologia. Barcelona (Spain).

Mutations of the TP53 tumor suppressor gene and nuclear accumulation of abnormal p53 proteins are common in colon and bladder cancer, and have been associated with clinical aggressiveness and poor response to specific therapies. However, there is no general agreement regarding the optimal technical approach to define the TP53 status […]

2003-02-23T16:49:37+00:00